biofrontera pharma gmbh is a pharmaceuticals company based out of 104 waldhofer straße, heidelberg, bw, germany.
Company profile
Ticker
BFRI
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Bio-Fri GmbH ...
IRS number
473765675
BFRI stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
23 Apr 24
DEF 14A
Definitive proxy
17 Apr 24
8-K/A
Other Events
3 Apr 24
8-K
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
26 Mar 24
DEF 14A
Definitive proxy
20 Mar 24
S-1/A
IPO registration (amended)
19 Mar 24
8-K
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
15 Mar 24
10-K
2023 FY
Annual report
15 Mar 24
S-1
IPO registration
8 Mar 24
PRE 14A
Preliminary proxy
8 Mar 24
Transcripts
BFRI
Earnings call transcript
2023 Q4
18 Mar 24
BFRI
Earnings call transcript
2023 Q3
10 Nov 23
BFRI
Earnings call transcript
2023 Q2
11 Aug 23
BFRI
Earnings call transcript
2023 Q1
12 May 23
BFRI
Earnings call transcript
2022 Q4
8 Mar 23
BFRI
Earnings call transcript
2022 Q3
14 Nov 22
BFRI
Earnings call transcript
2022 Q2
12 Aug 22
BFRI
Earnings call transcript
2022 Q1
13 May 22
BFRI
Earnings call transcript
2021 Q4
8 Apr 22
BFRI
Earnings call transcript
2021 Q3
1 Dec 21
Latest ownership filings
SC 13G
Rosalind Advisors, Inc.
21 Mar 24
SC 13G
Rosalind Advisors, Inc.
20 Mar 24
SC 13G
LYTTON LAURENCE W
20 Mar 24
SC 13G
HIRSCHMAN ORIN
20 Mar 24
SC 13G
Bigger Capital, LLC
15 Mar 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
3
Heikki Lanckriet
22 Aug 23
4
Erica L. Monaco
22 May 23
4
Hermann Luebbert
22 May 23
4
Eugene Frederick Leffler
12 Jan 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.62 mm | 3.62 mm | 3.62 mm | 3.62 mm | 3.62 mm | 3.62 mm |
Cash burn (monthly) | 343.67 k | 2.01 mm | 2.11 mm | 2.44 mm | 668.00 k | 2.03 mm |
Cash used (since last report) | 2.35 mm | 13.78 mm | 14.48 mm | 16.70 mm | 4.57 mm | 13.87 mm |
Cash remaining | 1.27 mm | -10.16 mm | -10.85 mm | -13.08 mm | -952.80 k | -10.25 mm |
Runway (months of cash) | 3.7 | -5.0 | -5.1 | -5.4 | -1.4 | -5.1 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 17 |
Opened positions | 3 |
Closed positions | 4 |
Increased positions | 3 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 425.76 mm |
Total shares | 5.44 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Abshagen Consulting GmbH | 3.15 mm | $3.68 mm |
Deutsche Balaton Aktiengesellschaft | 1.18 mm | $1.41 mm |
Bard Associates | 392.20 k | $121.53 mm |
Vanguard | 219.05 k | $113.91 mm |
Advisor | 121.77 k | $19.24 mm |
BLK Blackrock | 92.42 k | $48.06 mm |
Schonfeld Strategic Advisors | 88.50 k | $46.02 mm |
Geode Capital Management | 81.28 k | $42.27 mm |
Renaissance Technologies | 50.43 k | $26.00 k |
STT State Street | 22.90 k | $11.91 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 May 23 | Hermann Luebbert | Common Stock | Option exercise | Acquire M | No | No | 0 | 95,420 | 0.00 | 208,799 |
18 May 23 | Hermann Luebbert | RSU Commom Stock | Option exercise | Dispose M | No | No | 0 | 95,420 | 0.00 | 95,420 |
18 May 23 | Erica L. Monaco | Common Stock | Option exercise | Acquire M | No | No | 0 | 76,336 | 0.00 | 133,025 |
18 May 23 | Erica L. Monaco | RSU Commom Stock | Option exercise | Dispose M | No | No | 0 | 76,336 | 0.00 | 76,336 |
10 Jan 23 | Eugene Frederick Leffler | Employee stock option Common Stock | Grant | Acquire A | No | No | 0.9651 | 100,000 | 96.51 k | 100,000 |
News
12 Health Care Stocks Moving In Monday's After-Market Session
8 Apr 24
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
15 Mar 24
Earnings Scheduled For March 15, 2024
15 Mar 24
Biofrontera's Earnings Outlook
14 Mar 24
12 Health Care Stocks Moving In Thursday's After-Market Session
7 Mar 24
Press releases
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
26 Mar 24
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
15 Mar 24
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
15 Mar 24
Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
23 Feb 24
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use
5 Feb 24